tetano
Editor, Senior Moderator
CNS Neurosci Ther
. 2024 Jun;30(6):e14822.
doi: 10.1111/cns.14822. Evidences of neurological injury caused by COVID-19 from glioma tissues and glioma organoids
Huimin Hu[SUP] 1 2 3 4 5 [/SUP], Chen Wang[SUP] 1 2 3 4 5 [/SUP], Rui Tao[SUP] 1 2 3 4 5 [/SUP], Bohan Liu[SUP] 1 2 3 4 5 [/SUP], Dazhao Peng[SUP] 1 2 3 4 5 [/SUP], Yankun Chen[SUP] 1 2 3 4 5 [/SUP], Wei Zhang[SUP] 1 2 3 4 5 [/SUP]
Affiliations
Introduction: Despite the extensive neurological symptoms induced by COVID-19 and the identification of SARS-CoV-2 in post-mortem brain samples from COVID-19 patients months after death, the precise mechanisms of SARS-CoV-2 invasion into the central nervous system remain unclear due to the lack of research models.
Methods: We collected glioma tissue samples from glioma patients who had a recent history of COVID-19 and examined the presence of the SARS-CoV-2 spike protein. Subsequently, spatial transcriptomic analyses were conducted on normal brain tissues, glioma tissues, and glioma tissues from glioma patients with recent COVID-19 history. Additionally, single-cell sequencing data from both glioma tissues and glioma organoids were collected and analyzed. Glioma organoids were utilized to evaluate the efficacy of potential COVID-19 blocking agents.
Results: Glioma tissues from glioma patients with recent COVID-19 history exhibited the presence of the SARS-CoV-2 spike protein. Differences between glioma tissues from glioma patients who had a recent history of COVID-19 and healthy brain tissues primarily manifested in neuronal cells. Notably, neuronal cells within glioma tissues of COVID-19 history demonstrated heightened susceptibility to Alzheimer's disease, depression, and synaptic dysfunction, indicative of neuronal aberrations. Expressions of SARS-CoV-2 entry factors were confirmed in both glioma tissues and glioma organoids. Moreover, glioma organoids were susceptible to pseudo-SARS-CoV-2 infection and the infections could be partly blocked by the potential COVID-19 drugs.
Conclusions: Gliomas had inherent traits that render them susceptible to SARS-CoV-2 infection, leading to their representability of COVID-19 neurological symptoms. This established a biological foundation for the rationality and feasibility of utilization of glioma organoids as research and blocking drug testing model in SARS-CoV-2 infection within the central nervous system.
Keywords: COVID‐19; glioma tissues; organoid; spatial transcriptome.
. 2024 Jun;30(6):e14822.
doi: 10.1111/cns.14822. Evidences of neurological injury caused by COVID-19 from glioma tissues and glioma organoids
Huimin Hu[SUP] 1 2 3 4 5 [/SUP], Chen Wang[SUP] 1 2 3 4 5 [/SUP], Rui Tao[SUP] 1 2 3 4 5 [/SUP], Bohan Liu[SUP] 1 2 3 4 5 [/SUP], Dazhao Peng[SUP] 1 2 3 4 5 [/SUP], Yankun Chen[SUP] 1 2 3 4 5 [/SUP], Wei Zhang[SUP] 1 2 3 4 5 [/SUP]
Affiliations
- PMID: 38923860
- DOI: 10.1111/cns.14822
Introduction: Despite the extensive neurological symptoms induced by COVID-19 and the identification of SARS-CoV-2 in post-mortem brain samples from COVID-19 patients months after death, the precise mechanisms of SARS-CoV-2 invasion into the central nervous system remain unclear due to the lack of research models.
Methods: We collected glioma tissue samples from glioma patients who had a recent history of COVID-19 and examined the presence of the SARS-CoV-2 spike protein. Subsequently, spatial transcriptomic analyses were conducted on normal brain tissues, glioma tissues, and glioma tissues from glioma patients with recent COVID-19 history. Additionally, single-cell sequencing data from both glioma tissues and glioma organoids were collected and analyzed. Glioma organoids were utilized to evaluate the efficacy of potential COVID-19 blocking agents.
Results: Glioma tissues from glioma patients with recent COVID-19 history exhibited the presence of the SARS-CoV-2 spike protein. Differences between glioma tissues from glioma patients who had a recent history of COVID-19 and healthy brain tissues primarily manifested in neuronal cells. Notably, neuronal cells within glioma tissues of COVID-19 history demonstrated heightened susceptibility to Alzheimer's disease, depression, and synaptic dysfunction, indicative of neuronal aberrations. Expressions of SARS-CoV-2 entry factors were confirmed in both glioma tissues and glioma organoids. Moreover, glioma organoids were susceptible to pseudo-SARS-CoV-2 infection and the infections could be partly blocked by the potential COVID-19 drugs.
Conclusions: Gliomas had inherent traits that render them susceptible to SARS-CoV-2 infection, leading to their representability of COVID-19 neurological symptoms. This established a biological foundation for the rationality and feasibility of utilization of glioma organoids as research and blocking drug testing model in SARS-CoV-2 infection within the central nervous system.
Keywords: COVID‐19; glioma tissues; organoid; spatial transcriptome.